[Translation] A clinical study to evaluate the pharmacokinetics and pharmacodynamics of rhenium [188Re] etidronate injection in patients with castration-resistant prostate cancer and bone metastases

评估去势抵抗性前列腺癌骨转移患者单次静脉注射铼[188Re]依替膦酸盐注射液的药代动力学（PK）和药效学（PD）特征，为后续临床剂量选择提供依据。

[Translation]

To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of a single intravenous injection of rhenium [188Re] etidronate injection in patients with castration-resistant prostate cancer bone metastases, and to provide a basis for subsequent clinical dose selection.

Start Date15 Jun 2020

Sponsor / Collaborator

Jiangsu Rhentai Pharmaceutical Biotechnology Co., Ltd.

[+1]

CTR20181152

/ CompletedPhase 2

多中心、随机、双盲、安慰剂平行对照评价[188Re]依替膦酸盐注射液对CRPC癌骨转移患者的耐受性、有效性和安全性

[Translation] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the tolerability, efficacy, and safety of [188Re] etidronate injection in patients with CRPC bone metastasis

评价多次应用188Re-HEDP 对去势抵抗性前列腺癌骨转移患者的耐受性、有效性和安全性

[Translation]

To evaluate the tolerability, efficacy and safety of multiple administrations of 188Re-HEDP in patients with castration-resistant prostate cancer bone metastases

Start Date24 Oct 2018

Sponsor / Collaborator

Jiangsu Rhentai Pharmaceutical Biotechnology Co., Ltd.

[+1]

CTR20130708

/ CompletedPhase 2

铼[188Re]依替膦酸盐注射液对肿瘤骨转移镇痛作用Ⅱa期多中心、随机、盲法探索性临床研究

[Translation] Phase IIa multicenter, randomized, blinded exploratory clinical study on the analgesic effect of rhenium [188Re] etidronate injection on tumor bone metastasis

进一步评价铼[188Re]依替膦酸盐注射液（30MBq/kg、40MBq/kg、50MBq/kg）对肿瘤骨转移疼痛的镇痛疗效和安全性，根据IIa期研究结果选择合适的剂量，进入IIb期研究。

[Translation]

To further evaluate the analgesic efficacy and safety of rhenium [188Re] etidronate injection (30MBq/kg, 40MBq/kg, 50MBq/kg) for pain caused by tumor bone metastasis, select the appropriate dose based on the results of the Phase IIa study, and enter the Phase IIb study.

Start Date12 Sep 2013

Sponsor / Collaborator

Jiangsu Rhentai Pharmaceutical Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai Institute of Applied Physics, Chinese Academy of Sci

0 Patents (Medical) associated with Shanghai Institute of Applied Physics, Chinese Academy of Sci

Literatures (Medical) associated with Shanghai Institute of Applied Physics, Chinese Academy of Sci

01 Feb 2025·Journal for ImmunoTherapy of Cancer

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis

Article

Author: Huang, Qingqing ; Yang, Hao ; Wang, Tong ; Yang, Lin ; Li, Xingxing ; Huang, Gang ; Wang, Jin ; Mao, Shuyang ; Liu, Yuxia ; Xie, Haiyan ; Xu, Jing ; Li, Danfang ; Wu, Lisha ; Wang, Chenyue ; Xie, Wei ; Zhang, Xiaofei ; Wang, Zitong

BackgroundHypoxia is associated with the evasion of triple-negative breast cancer (TNBC) from immune surveillance. Hypoxia increases the subpopulation of putative TNBC stem-like cells (TNBCSCs) through activating Wnt/β-Catenin signaling. The shedding of MHC class I-related chain A (MICA) is particularly noteworthy in cancer stem cells (CSCs), promoting the resistance of CSCs to natural killer (NK) cell cytotoxicity. To reestablish MICA/NKG2D-mediated immunosurveillance, we proposed the design of a fusion protein (SHH002-hu1-MICA) which consists of Frizzled-7 (Fzd7)-targeting antibody and MICA, serving as an engager retargeting NK cells against TNBCs, especially TNBCSCs.MethodsOpal multicolor immunohistochemistry staining was used to validate the expression of membrane MICA (mMICA) and existence of NK cells in TNBC tumors; flow cytometry (FCM) assay was used to detect the expression of Fzd7/mMICA on TNBCs. Biolayer interferometry (BLI) and surface plasmon resonance (SPR) assays were executed to assess the affinity of SHH002-hu1-MICA towards rhFzd7/rhNKG2D; near-infrared imaging assay was used to evaluate the targeting capability. A cytotoxicity assay was conducted to assess the effects of SHH002-hu1-MICA on NK cell-mediated killing of TNBCs, and FCM assay to analyze the effects of SHH002-hu1-MICA on the degranulation of NK cells. Finally, TNBC cell-line-derived xenografts were established to evaluate the anti-tumor activities of SHH002-hu1-MICA in vivo.ResultsThe expression of mMICA is significantly downregulated in hypoxic TNBCs and TNBCSCs, leading to the evasion of immune surveillance exerted by NK cells. The expression of Fzd7 is significantly upregulated in TNBCSCs and exhibits a negative correlation with the expression of mMICA and infiltration level of NK cells. On accurate assembly, SHH002-hu1-MICA shows a strong affinity for rhFzd7/rhNKG2D, specifically targets TNBC tumor tissues, and disrupts Wnt/β-Catenin signaling. SHH002-hu1-MICA significantly enhances the cytotoxicity of NK cells against hypoxic TNBCs and TNBCSCs by inducing the degranulation of NK cells and promotes the infiltration of NK cells in CD44highregions within TNBC xenograft tumors, exhibiting superior anti-tumor activities than SHH002-hu1.ConclusionsSHH002-hu1-MICA maintains the targeting property of SHH002-hu1, successfully activates and retargets NK cells against TNBCs, especially TNBCSCs, exhibiting superior antitumor activities than SHH002-hu1. SHH002-hu1-MICA represents a promising new engager for NK cell-based immunotherapy for TNBC.

01 Jun 2024·IEEE Sensors Journal

Low-Energy X-Ray Dosimeter Using YAG:Yb Crystal-Derived Silica Fiber

Author: Bella Christy, Yollanda ; Guo, Qiang ; Peng, Gangding ; Li, Haoyu ; Luo, Xulin ; Xu, Chao ; Shen, Rongfang ; Li, Yahui

The YAG:Yb crystal-derived silica fiber (YCDSF) was fabricated using the modified rod-in-tube (RIT) method.The distribution of elements and optical properties of the fiber samples were investigated through energy dispersive X-ray spectrometer (EDS), refractive index, transmission loss, and photoluminescence (PL) measurements.YCDSF served as the X-ray dosimeter probe.The radioluminescence (RL) characteristics of the dosimeter were investigated over a dose rate range of 0.944-4.267 Gy/min and a dose range of 0.314-1.422 Gy.The results show that the dosimeter has a certain linear relationship response.Repeatability test results show that the dosimeter exhibits both repeatability and stability.Simultaneously, the radiation response of the dosimeter was investigated within the X-ray tube voltage range of 40-80 kV.The outcomes reveal a discernible linear relationship for the dosimeter in the low-energy radiotherapy range.These results suggest that the fast UV scintillation properties of YAG:Yb hold potential for applications in remote radiotherapy and real-time dose monitoring.

01 Jan 2024·Nuclear Science and Techniques

Conceptual design of a 714-MHz RFQ for compact proton injectors and development of a new tuning algorithm on its aluminium prototype

Author: Guo, Yu-Sen ; Lu, Yi-Xing ; Fang, Wen-Cheng ; Zhao, Zhen-Tang

Abstract: Radio frequency quadrupoles (RFQs), which are crucial components of proton injectors, significantly affect the performance of proton accelerator facilities.An RFQ with a high frequency of 714 MHz dedicated to compact proton injectors for medical applications is designed in this study.The RFQ is designed to accelerate proton beams from 50 keV to 4 MeV within a short length of 2 m and can be matched closely with the downstream drift tube linac to capture more particles through a preliminary optimization.To develop an advanced RFQ, challenging techniques, including fabrication and tuning method, must be evaluated and verified using a prototype.An aluminum prototype is derived from the conceptual design of the RFQ and then redesigned to confirm the radio frequency performance, fabrication procedure, and feasibility of the tuning algorithm.Eventually, a new tuning algorithm based on the response matrix and least-squares method is developed, which yields favorable results based on the prototype, i.e., the errors of the dipole and quadrupole components reduced to a low level after several tuning iterations.Benefiting from the conceptual design and techniques obtained from the prototype, the formal mech. design of the 2-m RFQ is ready for the next manufacturing step.

100 Deals associated with Shanghai Institute of Applied Physics, Chinese Academy of Sci

100 Translational Medicine associated with Shanghai Institute of Applied Physics, Chinese Academy of Sci

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

188Re-HEDP	Adenocarcinoma of prostate More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Shanghai Institute of Applied Physics, Chinese Academy of Sci

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 May 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing